Feedback PLC Adoption of TexRAD research software (6329K)

TIDMFDBK

RNS Number : 6329K

Feedback PLC

20 April 2015

20 April 2015

Feedback plc

("Feedback", the "Company")

Adoption of TexRAD research software

Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce the adoption of its TexRAD research software by four further leading cancer research institutions.

   1)    The Evangelische Lungenklinik Berlin (ELK) 

ELK is an internationally recognisedspecialist hospital for diseases of the chest treating more than 18,000 patients annually. The sale of the TexRAD research software to the Radiology Department at ELK is our first sale into Germany. This installation will be used to evaluate lung cancer treatment outcomes, one of the leading causes of cancer mortality and a key area of interest for TexRAD.

   2)    Velindre Cancer Centre, Cardiff, Wales, UK 

This first sale in Wales is an important milestone in the development phase of TexRAD where the Company's software is being used by clinical oncologists as a research tool in assessing tumour heterogeneity as a way of monitoring the progression and response of tumours to therapy.

   3)    University of Tokyo, Department of Radiology at the Institute of Medical Science 

Japan has one of the highest numbers of CT and MRI scanners per capita in the world. This leading research institute joins the Company's growing list of adopters to use TexRAD software for research purposes.

   4)    Centre Hospitalier Universitaire De Reims, Reims, France 

This is the Company's first major hospital site outside Paris, where it already has two prestigious sites as users. Here the Company will be providing a customised laptop solution (rather than the Company's standard server-based solution) demonstrating its flexibility in meeting the specific requirements of clients.

These recent sales of TexRAD, together with others over the last two months with a combined sales value of over GBP100,000, are a further indication of the interest in TexRAD as a potentially valuable quantitative tool in cancer research. The revenue associated with these sales will be recognised over the life of the 12 month contracts in accordance with the Company's revenue recognition accounting policy.

Tom Charlton, Director of Feedback plc, commented:

"We are delighted by the interest from leading centres of oncology research in using our TexRAD texture analysis software"

For further information contact:

 
 Feedback plc                        Tel: 01954 
                                         718072 
 Simon Barrell / Trevor Brown 
  / Tom Charlton 
 
 Sanlam Securities UK (Nominated Adviser and 
  Joint Broker) 
 Simon Clements / Virginia Bull   Tel: [phone] 
                                           2200 
 
 Peterhouse Corporate Finance     Tel: [phone] 
  Ltd (Joint Broker)                       0936 
 Lucy Williams / Duncan Vasey 
 

Notes to editors:

TexRAD (is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than it is currently possible to see with the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging-Biomarker') in confident decision-making: assessing the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'.TexRAD is manufactured under licence by the ISO 13485 certified company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGGUGGCUPAGQM